Webinar: What is the role of calprotectin in COVID-19

The role of calprotectin in COVID-19

Clinical studies report increased levels of calprotectin in patients with severe SARS-CoV-2 infection, as well as identifying the ability of calprotectin to differentiate between mild and severe forms of the disease and its capability to predict the need for mechanical ventilation and mortality^1-6. This is valuable information that can help hospitals to better allocate essential resources that are often in limited supply.

In this webinar Gentian's VP Clinical Affairs Dr Aleksandra Havelka will give an introduction to the biomarker calprotectin in relation to severe COVID-19 and the hyper-inflammatory response, before she will go through several clinical studies discussing the value of calprotectin in COVID-19.

Watch webinar now

OR WATCH ON
YOUTUBE

GCAL® - Gentian's calprotectin immunoassay - early access to results

Gentian’s Calprotectin Immunoassay GCAL^® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA), and is therefore rapidly performed in only 10 minutes, making it extra beneficial when it is critical to get fast access to the results.

Learn more about GCAL® - contact us now

Do you have questions about GCAL^®  or calprotectin's role in COVID-19 send an email to marketing@gentian.com or fill out the form below:

References:

1. Shi H, Zuo Y, Yalavarthi S et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Journal of Leukocyte Biology. 2020;n/a(n/a).
2. Silvin A, Chapuis N et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell. 2020;182(6):1401-18.e18.
3. Chen L, Long X et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020;17(9):992-4.
4. Bauer W, Diehl-Wiesenecker E et al. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. J Infect. 2020.
5. Luis García de Guadiana R, Mulero MDR et al. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J Infect. 2020:S0163-4453(20)30543-0.
6. Udeh R, Advani S, de Guadiana Romualdo LG, Dolja-Gore X. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2021;10(4).